Tech-enabled drug discovery company Insilico Medicine secured $110 million in an oversubscribed Series E funding round.
A large equity fund of Value Partners Group, an asset management firm in Asia, and new and existing investors participated in the round.
WHAT IT DOES
Massachusetts-based Insilico's proprietary generative AI platform, Pharma.AI, utilizes biology, clinical medicine, scientific...
Manas AI, an AI-driven drug discovery platform, has launched with $24.6 million in seed funding in a round co-led by General Catalyst and LinkedIn cofounder Reid Hoffman.
Greylock and other strategic investors participated in the round.
LinkedIn cofounder Reid Hoffman and Dr. Siddhartha Mukherjee, an oncologist, researcher and author, founded Manas AI.
WHAT IT DOES
Manas AI is a drug discovery...
Absci, a data-first generative AI drug-creation company, is partnering with AMD, a semiconductor company, to deploy AMD Instinct accelerators and ROCm software to power vital AI drug-discovery workloads, as well as Absci's advanced De Novo antibody-design models.
In addition, AMD is making a $20 million investment in Absci. The investment will be structured as a private investment in public...
Drug discovery startup Insilico Medicine and Italian pharmaceutical company Menarini Group announced their second licensing agreement, which targets unmet needs in oncology with a novel AI-discovered preclinical asset.
The agreement grants Stemline Therapeutics, a subsidiary of Menarini, global rights to develop and commercialize a selective small molecule inhibitor with broad antitumor activity...
A consortium of research institutes in South Korea has been formed to promote the utilisation of AI and national supercomputers in discovering novel drugs for treating lung cancer.
According to a press statement, the following organisations will collaborate to develop and test AI for identifying novel drug candidates and predicting its efficacy:
DAAN Cancer Research Institute under Yonsei...
Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, has launched ProPhet, a startup using artificial intelligence to locate small molecules for drug discovery.
ProPhet was established following AION Labs' startup challenge focused on AI-powered drug discovery of new high-affinity small molecules.
The aim is to address the market need to speed...
Google DeepMind announced the launch of AlphaProteo, an AI system to help biological and health researchers design novel, high-strength proteins that bind to target molecules with accuracy and strength.
AlphaProteo was trained on the Protein Data Bank (PDB) that enables breakthroughs in science and education by providing access and tools for exploration, visualization and analysis of...
Israeli startup CytoReason, maker of a computation model to map and compare treatments, announced it secured $80 million in funding.
Pfizer, OurCrowd, NVIDIA and Thermo Fisher Scientific participated in the round.
WHAT IT DOES
CytoReason offers life sciences companies AI-enabled tools to gather data-driven and molecular-level insights to improve phase 2 success in clinical trials and optimize...
Amazon Web Services (AWS) announced that it is collaborating with EvolutionaryScale, an AI company focused on biology, to give scientists and researchers access to the startup's ESM3 language models via AWS to advance drug discovery by allowing for the creation of new proteins.
Yesterday, EvolutionaryScale, founded by former researchers at Meta’s AI research lab, announced it secured $142 million...
Google Research and Google DeepMind recently released a paper announcing the creation of a new LLM for drug discovery and therapeutic development dubbed Tx-LLM, fine-tuned from PaLM-2.
Tx-LLM utilizes the tech giant's PaLM-2, its generative AI technology that uses Google's LLMs to answer medical questions.
The drug discovery-focused LLM was trained using 709 datasets to target 66 tasks across...
